Business Wire - December 8, 2008
"We are pleased to be working with ReceptoPharm to have them supply us with the necessary quantities of GMP-certified CB-24 required to complete our planned Phase I clinical trial in France," explained John Reid, Managing Director of Celtic Biotech. "Working with ReceptoPharm and its scientific team, comprised of biologics specialists, allows us to feel confident that we will be using the highest quality product in our study," he continued.
Currently, ReceptoPharm is focused on developing novel therapies for neurological, viral, and autoimmune disorders. The contract from Celtic Biotech represents the first of such for the Company. Completing the contract will be an important milestone for ReceptoPharm, as it provides the Company with its first source of externally generated revenues.
"Expanding our business into outsourced drug production allows ReceptoPharm to fully utilize its GMP-qualified production facilities and provides the Company with an additional revenue stream," commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. "We plan to offer this service to other developmental stage biotechnology firms in addition to continuing our own clinical development initiatives," he concluded.
Recently, ReceptoPharm announced the completion of its Phase IIb/IIIa clinical trial for the treatment of Adrenomyeloneuropathy. Upon completing the study, the Company agreed to provide ongoing drug provisions to patients enrolled in the study. Data from the trial is expected to be published in early 2009.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.NutraPharma.com
http://www.ReceptoPharm.com
SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Providing clinical drug supplies to Celtic Biotech should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Contacts
Nutra Pharma Corp. | Investor Relations | David Isserman, 877-895-5647 | IR@nutrapharma.com
081208
BW081220
Copyright © 2008 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .